AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12470179 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (3000 mg)
Number of subjects: 10
Study 12470179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11289465 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-Family Systems Therapy (BFST)
Number of subjects: 119
Study 11289465 — intervention group
Group type: COMPARATOR
Intervention: Current Therapy (CT)
Number of subjects: 119
Study 11289465 — intervention group
Group type: COMPARATOR
Intervention: Education and Support (ES)
Number of subjects: 119
Study 9286892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 microg/kg 1.5 h before hemodynamic determinations) followed by intravenous epinephrine-containing test dose
Number of subjects: 18
Study 9286892 — intervention group
Group type: EXPERIMENTAL
Intervention: No premedication followed by intravenous test dose containing 3 ml of 1.5% lidocaine + 15 microg epinephrine
Number of subjects: 18
Study 9286892 — intervention group
Group type: COMPARATOR
Intervention: No premedication followed by intravenous saline 3 ml
Number of subjects: 18
Study 9286892 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine (5 microg/kg 1.5 h before hemodynamic determinations) followed by intravenous saline
Number of subjects: 18
Study 7900069 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY U3405 (20 mg four times a day from day 1 to day 3)
Number of subjects: 16
Study 3226967 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed visual stimuli for poetic metaphors (43 writers)
Number of subjects: 171
Study 3226967 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed visual stimuli for poetic metaphors (46 writers)
Number of subjects: 171
Study 3226967 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed images for drawings (43 artists)
Number of subjects: 171
Study 3226967 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed images constructed into a single-image figure-ground display (39 artists)
Number of subjects: 171
Study 3226967 — intervention group
Group type: COMPARATOR
Intervention: Control condition for poetic metaphors (43 writers)
Number of subjects: 171
Study 3226967 — intervention group
Group type: COMPARATOR
Intervention: Control condition for poetic metaphors (46 writers)
Number of subjects: 171
Study 3226967 — intervention group
Group type: COMPARATOR
Intervention: Control condition for drawings (43 artists)
Number of subjects: 171
Study 3226967 — intervention group
Group type: COMPARATOR
Intervention: Control condition for drawings (39 artists)
Number of subjects: 171
Study 1993628 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (60.0 Gy)
Number of subjects: 277
Study 1993628 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation therapy (50.0 Gy)
Number of subjects: 277
Study 1993628 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (60.0 Gy) in supraglottic larynx patients
Number of subjects: 277
Study 1993628 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation therapy (50.0 Gy) in supraglottic larynx patients
Number of subjects: 277
Study 795362 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 795362 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20
Study 795362 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 20
Study 795362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31471079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized stroke patients
Number of subjects: 364
Study 31471079 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational status (illiterate/unable to read and write)
Number of subjects: 364
Study 31471079 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending secondary school
Number of subjects: 364
Study 31471079 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay >5 days
Number of subjects: 364
Study 31350916 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg intravenously three times daily, maximum 20 mg daily)
Number of subjects: 1000
Study 31350916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline 0.9%)
Number of subjects: 1000
Study 31350916 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1000
Study 29489982 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized out‐of‐hospital management method
Number of subjects: 217
Study 29489982 — intervention group
Group type: COMPARATOR
Intervention: Dysphagia rehabilitation guidance (Control)
Number of subjects: 217
Study 26915028 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 75
Study 26915028 — intervention group
Group type: COMPARATOR
Intervention: Red laser treatment
Number of subjects: 75
Study 26915028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 75
Study 25623461 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment in PCOS patients (Group B)
Number of subjects: 186
Study 25623461 — intervention group
Group type: COMPARATOR
Intervention: Metformin treatment in PCOS patients (Group A)
Number of subjects: 186
Study 25623461 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients with insulin resistance
Number of subjects: 186
Study 25623461 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 186
Study 23139614 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression in LNM CRC
Number of subjects: 96
Study 23139614 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression in relation to advanced tumor node metastasis stage
Number of subjects: 96
Study 23139614 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression and 5‐year recurrence rate
Number of subjects: 96
Study 23139614 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression and 5‐year overall survival rate
Number of subjects: 96
Study 23139614 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression as a prognostic factor for recurrence
Number of subjects: 96
Study 23139614 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP‐1 expression as a prognostic factor for survival
Number of subjects: 96
Study 19465554 — intervention group
Group type: EXPERIMENTAL
Intervention: CO breathing (1 h/day at 100 parts/million for 5 days)
Number of subjects: 10
Study 19465554 — intervention group
Group type: EXPERIMENTAL
Intervention: CO breathing
Number of subjects: 10
Study 19465554 — intervention group
Group type: COMPARATOR
Intervention: Vo(2max) testing alone
Number of subjects: 10
Study 17458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for care-giving relatives
Number of subjects: 254
Study 17458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 254
Study 17458361 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study 15282204 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoadjusted CPAP titration
Number of subjects: 360
Study 15282204 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted formula titration with domiciliary adjustment
Number of subjects: 360
Study 15282204 — intervention group
Group type: COMPARATOR
Intervention: Standard CPAP titration (polysomnography)
Number of subjects: 360
Study 12221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of [(13)C(5)]pABG (376 nmol or 100 micro g) in 40 mL apple juice
Number of subjects: 4
Study 12221219 — intervention group
Group type: EXPERIMENTAL
Intervention: [(13)C(5)]pABG administered
Number of subjects: 4
Study 12221219 — intervention group
Group type: COMPARATOR
Intervention: Folate intake (450 or 850 micro g/d)
Number of subjects: 4
Study 12221219 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy status
Number of subjects: 4
Study 12221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall contribution of dietary pABG
Number of subjects: 4
Study 9803329 — intervention group
Group type: EXPERIMENTAL
Intervention: EVITA-2, CPAP 5 mbar
Number of subjects: 9
Study 9803329 — intervention group
Group type: EXPERIMENTAL
Intervention: SV 300, CPAP 5 mbar, flow trigger
Number of subjects: 9
Study 9803329 — intervention group
Group type: EXPERIMENTAL
Intervention: SV 300, pressure trigger - 4 mbar
Number of subjects: 9
Study 9803329 — intervention group
Group type: EXPERIMENTAL
Intervention: EVITA-4, CPAP 5 mbar
Number of subjects: 9
Study 9803329 — intervention group
Group type: COMPARATOR
Intervention: SV 300 with 2 mbar pressure support
Number of subjects: 9
Study 7796721 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised therapy and dispensing of AZT for eight weeks
Number of subjects: 27
Study 7796721 — intervention group
Group type: COMPARATOR
Intervention: Usual care of the clinic
Number of subjects: 27
Study 7796721 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised therapy and dispensing of AZT
Number of subjects: 27
Study 2192018 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ 50 mg/kg per day for 15 days
Number of subjects: 114
Study 2192018 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ 50 mg/kg per day for 8 days
Number of subjects: 114
Study 2192018 — intervention group
Group type: EXPERIMENTAL
Intervention: ALB 15 mg/kg per day for 30 days
Number of subjects: 114
Study 2192018 — intervention group
Group type: EXPERIMENTAL
Intervention: ALB 15 mg/kg per day for 8 days
Number of subjects: 114
Study 2192018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 114
Study 116273 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (5 microgram/kg administered IV)
Number of subjects: 28
Study 116273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30003521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral maternal vitamin B12 supplementation
Number of subjects: 218
Study 30003521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 30003521 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum total homocysteine (tHcy) in the second trimester
Number of subjects: 218
Study 30003521 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum total homocysteine (tHcy) in the third trimester
Number of subjects: 218
Study 30003521 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal serum total homocysteine (tHcy) levels
Number of subjects: 218
Study 28687828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical feedback
Number of subjects: 60
Study 28687828 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory feedback
Number of subjects: 60
Study 28687828 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 60
Study 25725178 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 96
Study 25725178 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 96
Study 23529102 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback with kinetic guidance
Number of subjects: 0
Study 23529102 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback with kinetic guidance (Control)
Number of subjects: 0
Study 21507527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone protocol (1 mg IV followed by 1 mg IV after 15 minutes if needed)
Number of subjects: 338
Study 21507527 — intervention group
Group type: COMPARATOR
Intervention: Usual care (any intravenous opioid at physician's discretion)
Number of subjects: 338
Study 19142106 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg/d
Number of subjects: 14
Study 19142106 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 14
Study 17381399 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (TOBI)
Number of subjects: 10
Study 17381399 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin (TOBRA)
Number of subjects: 10
Study 15133405 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR 80 mg/d
Number of subjects: 434
Study 15133405 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR 120 mg/d
Number of subjects: 434
Study 15133405 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR 160 mg/d
Number of subjects: 434
Study 15133405 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR 640 mg/d
Number of subjects: 434
Study 15133405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 12492136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PRO)
Number of subjects: 5
Study 12492136 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GLY)
Number of subjects: 5
Study 12492136 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study 12492136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen breathing at SL concentration
Number of subjects: 5
Study 9799974 — intervention group
Group type: COMPARATOR
Intervention: CDSB Qi-training (more than 13 months)
Number of subjects: 164
Study 9799974 — intervention group
Group type: COMPARATOR
Intervention: CDSB Qi-training (1-4 months)
Number of subjects: 164
Study 9799974 — intervention group
Group type: COMPARATOR
Intervention: CDSB Qi-training (5-12 months)
Number of subjects: 164
Study 9799974 — intervention group
Group type: COMPARATOR
Intervention: CDSB Qi-training (all groups)
Number of subjects: 164
Study 8745663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 mg twice a day)
Number of subjects: 87
Study 8745663 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinidine (300 mg twice a day)
Number of subjects: 87
Study 8745663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 87
Study 8745663 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinidine
Number of subjects: 87
Study 2762688 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.25‐0.3 mg)
Number of subjects: 18
Study 2762688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 941962 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual-motor training program (30 minutes per day, 5 days per week for 10 weeks)
Number of subjects: 40
Study 941962 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual-motor training program
Number of subjects: 40
Study 941962 — intervention group
Group type: COMPARATOR
Intervention: Regular classroom activities (Control group)
Number of subjects: 40
Study 31089282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (IG: resistance, endurance, and flexibility training)
Number of subjects: 70
Study 31089282 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (CG: mental and relaxation training)
Number of subjects: 70
Study 31089282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 31089282 — intervention group
Group type: COMPARATOR
Intervention: Exercise intervention group (IG) vs Non-exercise control group (CG)
Number of subjects: 70
Study 29054505 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMonitor 2 Implantable Cardiac Monitor
Number of subjects: 30
Study 26439325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-HCT Medical Outcomes Study Short Form-36 Health Survey (SF-36) physical component summary (PCS) scale
Number of subjects: 646
Study 26439325 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-HCT decreases in PCS
Number of subjects: 646
Study 26439325 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 PCS adjusted for patient variables in the US Stem Cell Therapeutic Outcomes Database model
Number of subjects: 646
Study 25262224 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy (SP)
Number of subjects: 32
Study 25262224 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy with autotransplantation (TP/AT)
Number of subjects: 32
Study 22935584 — intervention group
Group type: EXPERIMENTAL
Intervention: OxCap (oxaliplatin/capecitabine)
Number of subjects: 2397
Study 22935584 — intervention group
Group type: COMPARATOR
Intervention: OxFU (oxaliplatin/leucovorin/infusional 5-FU)
Number of subjects: 2397
Study 22935584 — intervention group
Group type: COMPARATOR
Intervention: OxFU+cetuximab
Number of subjects: 2397
Study 22935584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (OxCap and OxFU)
Number of subjects: 2397
Study 20224060 — intervention group
Group type: EXPERIMENTAL
Intervention: simplified mRS questionnaire (smRSq)
Number of subjects: 50
Study 20224060 — intervention group
Group type: COMPARATOR
Intervention: structured interview mRS
Number of subjects: 50
Study 17581320 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose hormone therapy
Number of subjects: 202
Study 17581320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy
Number of subjects: 202
Study 17581320 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 202
Study 17581320 — intervention group
Group type: COMPARATOR
Intervention: Tibolone
Number of subjects: 202
Study 15839851 — intervention group
Group type: EXPERIMENTAL
Intervention: almotriptan
Number of subjects: 18
Study 15839851 — intervention group
Group type: EXPERIMENTAL
Intervention: lysine-acetylsalicylate
Number of subjects: 18
Study 15839851 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 12431829 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy (vinorelbine or gemcitabine)
Number of subjects: 707
Study 12431829 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy (gemcitabine plus vinorelbine)
Number of subjects: 707
Study 9655013 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended locations
Number of subjects: 0
Study 9655013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear stimuli
Number of subjects: 0
Study 9655013 — intervention group
Group type: COMPARATOR
Intervention: Unattended locations
Number of subjects: 0
Study 9655013 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual quality
Number of subjects: 0
Study 7659427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory examination in the painful area using various stimuli (heat, cold, argon laser, von Frey hair)
Number of subjects: 11
Study 2664522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily during the third trimester)
Number of subjects: 65
Study 2664522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the third trimester)
Number of subjects: 65
Study 178190 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term hospitalization
Number of subjects: 141
Study 178190 — intervention group
Group type: COMPARATOR
Intervention: Short-term hospitalization
Number of subjects: 141
Study 31045443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound assessment at baseline (1.15 ± 1.80) and at high altitude (2.56 ± 2.86)
Number of subjects: 103
Study 31045443 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants diagnosed with AMS
Number of subjects: 103
Study 31045443 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in BLS (ΔBLS) from low altitude baseline
Number of subjects: 103
Study 27989394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined functional voice therapy (10-15 individual sessions, 30-40 minutes each)
Number of subjects: 40
Study 27989394 — intervention group
Group type: COMPARATOR
Intervention: Control group (singers who did not opt for vocal rehabilitation)
Number of subjects: 40
Study 25687666 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise training regimen (cycle ergometry), 3 days/week for 3 months.
Number of subjects: 54
Study 25687666 — intervention group
Group type: COMPARATOR
Intervention: Stretching activities (attention-control condition), same contact time as exercise condition.
Number of subjects: 54
Study 23196701 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 487
Study 23196701 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine and hydroxychloroquine (SSZ+HCQ)
Number of subjects: 487
Study 23196701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 487
Study 21531412 — intervention group
Group type: COMPARATOR
Intervention: Multiple 7F double‐pigtail stents (group A)
Number of subjects: 51
Study 21531412 — intervention group
Group type: EXPERIMENTAL
Intervention: Stents in combination with UDCA and terpene (group B)
Number of subjects: 51
Study 18460483 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (40g/day of ground flaxseed-containing baked products)
Number of subjects: 62
Study 18460483 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed
Number of subjects: 62
Study 18460483 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran products (control)
Number of subjects: 62
Study 16307723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (15 mmol L(‐1) solution dripped onto enamel blocks eight times per day)
Number of subjects: 12
Study 16307723 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (dripped onto enamel blocks eight times per day)
Number of subjects: 12
Study 12754275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment for 6 weeks
Number of subjects: 18
Study 12754275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 10726678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (PS)
Number of subjects: 100
Study 10726678 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular clinical and endoscopic examinations)
Number of subjects: 100
Study 8933117 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-fortified margarine (250 g per week providing 28.8 micrograms retinol equivalents per gram)
Number of subjects: 581
Study 8933117 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified margarine (0 microgram retinol equivalents)
Number of subjects: 581
Study 7956275 — intervention group
Group type: COMPARATOR
Intervention: Sterile gauze and tape (control), replaced every 2 days
Number of subjects: 442
Study 7956275 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional polyurethane dressing, replaced every 5 days
Number of subjects: 442
Study 7956275 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly permeable polyurethane dressing, replaced every 5 days
Number of subjects: 442